PGNX stock forecast
Our latest prediction for Progenics Pharmaceuticals, Inc.'s stock price was made on the Sept. 9, 2019 when the stock price was at 5.01$.
In the short term (2weeks), PGNX's stock price should outperform the market by 3.46%. During that period the price should oscillate between -8.54% and +14.43%.
In the medium term (3months), PGNX's stock price should outperform the market by 1.82%. During that period the price should oscillate between -19.83% and +33.89%.Get email alerts
Create a solid portfolio with PGNX
About Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
At the moment the company generates 23M USD in revenues.
On its last earning announcement, the company reported a loss of -0.93$ per share.
The book value per share is 0.74$
Three months stock forecastSept. 9, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|